Clinical trials
Lung Cancer (Locally Advanced or Metastatic) clinical trials
Below are recruiting lung cancer (locally advanced or metastatic) clinical trials, each written for real people, not researchers. We’re tracking 5,796 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06554652RecruitingPhase 3
Comparing two neck surgeries for thyroid cancer spread
This trial compares two types of neck surgery for people with papillary thyroid cancer that has spread to a small number of lymph nodes in the neck. The goal is to see if a less extensive lymph node removal works just as well as the standard more extensive surgery.
ShanghaiAges 14–80 - NCT06552234RecruitingPhase 2
Study of repotrectinib for older or frail patients with ROS1-positive lung cancer
This trial tests an oral targeted therapy called repotrectinib in people with advanced non-small cell lung cancer (NSCLC) that has a change in the ROS1 gene. It is designed for patients who are either 70 or older, or have a lower performance status (ECOG 2 or higher), meaning they may be more frail or have more symptoms. The goal is to see if repotrectinib can help shrink or control the cancer.
Aix-en-Provence, Bouches Du RhôneAges 18 years+ - NCT06558773RecruitingPhase 2
New drug combo for previously treated colorectal cancer
This trial tests a combination of a GSL synthesis inhibitor, an immunotherapy drug, and/or regorafenib in people with a specific type of colorectal cancer (pMMR/MSS) that has not responded to at least two prior treatments. The goal is to see if this new approach can help shrink or control the cancer.
Beijing, Biotherapeutic Department of Chinsese PLA Gereral HospitalAges 18–75 - NCT06555133RecruitingPhase 2
Study of Y-90, capecitabine, and atezolizumab for advanced colorectal cancer
This trial tests a combination of targeted radiation (Y-90), chemotherapy (capecitabine), and immunotherapy (atezolizumab) for people with colorectal cancer that has spread mainly to the liver and is no longer responding to at least two prior treatments. The goal is to see if this combination can shrink tumors or slow the disease.
Providence, Rhode IslandAges 18 years+ - NCT06546150RecruitingPhase 1
Cell therapy for KRAS G12V mutated advanced solid tumors
This trial tests a new immune cell therapy (called RE002 T cells) for people with advanced solid tumors that have a specific KRAS G12V mutation and a certain HLA type. The therapy is designed to target and attack cancer cells that carry this mutation.
Zhengzhou, HenanAges 18–75 - NCT06542757Recruiting
Focused radiation to main prostate tumor using MRI guidance
This trial tests a stronger, more focused radiation dose to the main tumor inside the prostate using MRI guidance. It aims to improve control of intermediate-risk prostate cancer while possibly reducing side effects.
New York, New YorkAges 18 years+ - NCT06541639RecruitingPhase 1
Immune cell therapy for advanced solid tumors
This study tests a new immune cell therapy (EVM16) given alone or with another drug (tislelizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination can help shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06528769RecruitingPhase 2
ATRA and immunotherapy for advanced leiomyosarcoma
This trial tests a combination of two drugs—all-trans retinoic acid (ATRA, a vitamin A derivative) and cemiplimab (an immunotherapy)—for people with advanced leiomyosarcoma who've already had chemotherapy. The goal is to see if this combination can shrink tumors or slow cancer growth.
Columbus, OhioAges 18 years+ - NCT06528496RecruitingPhase 2
Less chemo plus antibody therapy for high-risk neuroblastoma in children
This study tests whether giving fewer chemotherapy drugs along with other targeted therapies (monoclonal antibodies) works well for children with high-risk neuroblastoma. It aims to reduce side effects while still treating the cancer effectively.
New York, New YorkAges 1.5 years–19 years - NCT06531083Recruiting
Early monitoring and physical therapy to prevent jaw stiffness after radiation
This study tests whether a program of early monitoring and physical therapy can help prevent or reduce jaw stiffness (trismus) after radiation therapy for head and neck cancer. It is for patients who are about to start radiation and want to keep their jaw working well.
Edmonton, AlbertaAges 18 years+ - NCT06526104RecruitingPhase 2
Tremelimumab and durvalumab for advanced liver cancer with Child-Pugh B
This trial tests a combination of two immunotherapy drugs, tremelimumab and durvalumab, for people with advanced liver cancer (HCC) who have moderate cirrhosis (Child-Pugh B). The goal is to see if this treatment can shrink tumors or slow cancer growth.
San Antonio, TexasAges 18 years+ - NCT06530251RecruitingPhase 1/Phase 2
AK112 for advanced liver cancer (HCC)
This trial tests a new immunotherapy drug called AK112 for people with advanced liver cancer that hasn't spread to the brain or key blood vessels. It may be an option if you haven't had immunotherapy before and your liver is still working well.
Beijing, Beijing MunicipalityAges 18–75 - NCT06515314RecruitingPhase 1
TCR-T cell therapy for AFP-positive liver and other cancers
This trial tests an experimental cell treatment called HRYZ-T102 TCR-T for people with advanced liver cancer or other solid tumors that make a protein called AFP. The treatment uses your own immune cells, modified in a lab to target and kill cancer cells.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06526819RecruitingPhase 1/Phase 2
New drug SMP-3124LP for advanced solid tumors
This trial tests a new drug called SMP-3124LP for people with advanced solid tumors that no longer respond to standard treatments. It is given in two phases: first to find the best dose (dose escalation) and then to see how well it works in specific cancer types (dose expansion).
Los Angeles, CaliforniaAges 18 years+ - NCT06504732RecruitingPhase 2/Phase 3
IAH0968 plus CAPEOX for HER2-positive gastric cancer
This trial tests a new drug (IAH0968) combined with chemotherapy (CAPEOX) for people with HER2-positive stomach or gastroesophageal junction cancer that has not been treated before or has spread.
Harbin, HeilongjiangAges 18–75 - NCT06496256Recruiting
Barrigel gel for radiation after prostate removal
This trial tests a gel placed in the rectum during radiation therapy to protect healthy tissue after prostate removal. It is for men whose prostate cancer has come back (PSA rise) and who need radiation to the prostate bed.
Chandler, ArizonaAges 18 years+ - NCT06499870RecruitingPhase 2
Study of two drugs with radiation for high-risk prostate cancer
This trial tests whether combining two hormone therapy drugs, relugolix and enzalutamide, with radiation therapy can help treat very high-risk prostate cancer. The goal is to see if this combination is safe and effective for men whose cancer has a high chance of coming back.
Chicago, IllinoisAges 18 years+ - NCT06487078Recruiting
Study of Lorlatinib for untreated ALK-positive lung cancer
This study looks at how well and how safely the drug lorlatinib works in people with a certain type of advanced lung cancer (ALK-positive NSCLC) who have not had treatment for their advanced cancer yet. The goal is to see how effective it is in the real world.
Paris, ParisAges 18 years+ - NCT06479070Recruiting
Using ctDNA to guide radiotherapy for head and neck cancer
This study looks at whether measuring a DNA fragment in the blood (called ctDNA) can help predict how well radiotherapy works for head and neck cancer. It may help doctors better tailor treatment for patients with stage III or IV disease.
Caen, CaenAges 18 years+ - NCT06462794RecruitingPhase 1
Study of CX-801 for advanced solid tumors
This trial tests a new drug called CX-801 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06469008RecruitingPhase 1
Study of BL-B16D1 for advanced head and neck cancer and other solid tumors
This study tests a new drug, BL-B16D1, for people with advanced head and neck cancer or other solid tumors that have not been helped by standard treatments. The goal is to see if the drug is safe and effective.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06466434Recruiting
Prebiotic diet to boost immunotherapy for melanoma
This trial tests whether a special prebiotic diet can help your body's bacteria (microbiome) better respond to standard immunotherapy for advanced melanoma that cannot be removed by surgery. If you are starting your first immunotherapy, you may be able to join.
Houston, TexasAges 18 years+ - NCT06469710Recruiting
Collecting cancer cells from blood in metastatic prostate cancer
This trial is testing a blood-filtering procedure (leukapheresis) to collect special cancer cells that have broken away from the tumor. It may help doctors better understand your prostate cancer and guide future treatment.
ShanghaiAges 18–75 - NCT06463262Recruiting
Personalized markers for chordoma before surgery and radiation
This trial tests whether analyzing blood and tumor samples before and after radiation and surgery can help find personalized markers for chordoma. It is for patients with chordoma of the skull base, spine, or sacrum who will receive radiation before surgery.
Baltimore, MarylandAges 18 years+
Hear when a new Lung Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (locally advanced or metastatic)?
- Yes. Clin2 currently lists 5,796 recruiting lung cancer (locally advanced or metastatic) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (locally advanced or metastatic) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (locally advanced or metastatic) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Colorectal Cancer (Locally Advanced or Metastatic)
- Liver Cancer (Locally Advanced or Metastatic)
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.